S&P 500   4,075.39 (-0.12%)
DOW   34,279.31 (-0.90%)
QQQ   291.73 (-0.56%)
AAPL   147.35 (-0.46%)
MSFT   252.39 (-1.08%)
META   119.60 (+1.27%)
GOOGL   100.73 (-0.26%)
AMZN   95.49 (-1.09%)
TSLA   195.19 (+0.25%)
NVDA   168.92 (-0.18%)
NIO   12.18 (-4.69%)
BABA   86.19 (-1.56%)
AMD   76.91 (-0.93%)
T   19.22 (-0.31%)
MU   55.52 (-3.69%)
CGC   3.66 (+1.10%)
F   14.15 (+1.80%)
GE   85.13 (-0.98%)
DIS   96.98 (-0.91%)
AMC   7.63 (+5.53%)
PYPL   78.34 (-0.09%)
PFE   50.67 (+1.08%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.39 (-0.12%)
DOW   34,279.31 (-0.90%)
QQQ   291.73 (-0.56%)
AAPL   147.35 (-0.46%)
MSFT   252.39 (-1.08%)
META   119.60 (+1.27%)
GOOGL   100.73 (-0.26%)
AMZN   95.49 (-1.09%)
TSLA   195.19 (+0.25%)
NVDA   168.92 (-0.18%)
NIO   12.18 (-4.69%)
BABA   86.19 (-1.56%)
AMD   76.91 (-0.93%)
T   19.22 (-0.31%)
MU   55.52 (-3.69%)
CGC   3.66 (+1.10%)
F   14.15 (+1.80%)
GE   85.13 (-0.98%)
DIS   96.98 (-0.91%)
AMC   7.63 (+5.53%)
PYPL   78.34 (-0.09%)
PFE   50.67 (+1.08%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.39 (-0.12%)
DOW   34,279.31 (-0.90%)
QQQ   291.73 (-0.56%)
AAPL   147.35 (-0.46%)
MSFT   252.39 (-1.08%)
META   119.60 (+1.27%)
GOOGL   100.73 (-0.26%)
AMZN   95.49 (-1.09%)
TSLA   195.19 (+0.25%)
NVDA   168.92 (-0.18%)
NIO   12.18 (-4.69%)
BABA   86.19 (-1.56%)
AMD   76.91 (-0.93%)
T   19.22 (-0.31%)
MU   55.52 (-3.69%)
CGC   3.66 (+1.10%)
F   14.15 (+1.80%)
GE   85.13 (-0.98%)
DIS   96.98 (-0.91%)
AMC   7.63 (+5.53%)
PYPL   78.34 (-0.09%)
PFE   50.67 (+1.08%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.39 (-0.12%)
DOW   34,279.31 (-0.90%)
QQQ   291.73 (-0.56%)
AAPL   147.35 (-0.46%)
MSFT   252.39 (-1.08%)
META   119.60 (+1.27%)
GOOGL   100.73 (-0.26%)
AMZN   95.49 (-1.09%)
TSLA   195.19 (+0.25%)
NVDA   168.92 (-0.18%)
NIO   12.18 (-4.69%)
BABA   86.19 (-1.56%)
AMD   76.91 (-0.93%)
T   19.22 (-0.31%)
MU   55.52 (-3.69%)
CGC   3.66 (+1.10%)
F   14.15 (+1.80%)
GE   85.13 (-0.98%)
DIS   96.98 (-0.91%)
AMC   7.63 (+5.53%)
PYPL   78.34 (-0.09%)
PFE   50.67 (+1.08%)
NFLX   316.76 (+3.68%)
OTCMKTS:PBSV

Pharma-Bio Serv - PBSV Stock Forecast, Price & News

$0.77
0.00 (0.00%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.77
▼
$0.77
50-Day Range
$0.77
▼
$0.97
52-Week Range
$0.58
▼
$1.10
Volume
N/A
Average Volume
1,014 shs
Market Capitalization
$18.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PBSV stock logo

About Pharma-Bio Serv (OTCMKTS:PBSV) Stock

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Receive PBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter.

PBSV Stock News Headlines

November 18, 2022 | marketwatch.com
The Biopharma Report is one of the fastest-growing online newsletters focused on the pharmaceutical and biotechnology industry.
November 2, 2022 | marketwatch.com
Bioactive Wound Care Market is Estimated to Accelerate Industry Development in Pharma & Healthcare Sector with Top Key Players till 2028
October 22, 2022 | marketwatch.com
Bio Pharma Buffer Market Is Expected To Progress At A Fast Rate During Forecast 2022 To 2028
October 15, 2022 | investing.com
China Resources Boya Bio pharmaceutical Group Co Ltd (300294)
October 6, 2022 | marketwatch.com
Provention Bio, Sanofi Set Co-Promotion Pact for Teplizumab U.S. Launch
September 27, 2022 | markets.businessinsider.com
PharmAbcine to Participate in BIO-Europe 2022
September 26, 2022 | finance.yahoo.com
PBSV: Slow and steady wins the race.
September 21, 2022 | marketwatch.com
Biological Safety Cabinet Market New Investments Expected to Boost the Demand by 2027 with 7.6% CAGR | 123 Pages Report
September 14, 2022 | finance.yahoo.com
Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2022
September 13, 2022 | msn.com
Novartis to invest $ 300 million in early technical development capabilities for biotherapeutics
September 13, 2022 | technews.tmcnet.com
Psycheceutical Bioscience, Inc.'s CEO to Present at the Life Sciences Investor Forum on September 15
August 25, 2022 | msn.com
BridgeBio Pharma Earnings Perspective: Return On Capital Employed
August 22, 2022 | markets.businessinsider.com
Spear Bio's NAB-Sure™ Test Kit Aids Analysis of COVID-19 Immune Response
August 10, 2022 | markets.businessinsider.com
Tetra Bio-Pharma Announces New Positive Preclinical Results Of ARDS-003
August 8, 2022 | nasdaq.com
Brazil's Biolab buys Canada's Exzell Pharma
August 4, 2022 | markets.businessinsider.com
Expert Ratings for Biomarin Pharmaceutical
June 29, 2022 | finance.yahoo.com
PBSV: Lowering target; still a solid value
June 16, 2022 | marketwatch.com
Bio Pharma Buffer Market Size Comprehensive Analysis, Growth Forecast from 2020 to 2025
June 16, 2022 | seekingalpha.com
Pharma-Bio Serv reports Q2 results
June 14, 2022 | marketwatch.com
Global Bio Pharma Buffer Market 2022 Upcoming Trends, Regional Study, Top Manufacturers Profiles, SWOT Analysis and Forecast by 2028
June 14, 2022 | finance.yahoo.com
Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2022
June 13, 2022 | markets.businessinsider.com
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
June 1, 2022 | finance.yahoo.com
BDO’s BioProcess Technology Group to Present at the 2022 BIO International Convention
May 16, 2022 | msn.com
Spring Bio Solution awards its social media mandate to Verve Media
May 10, 2022 | nasdaq.com
Why Biohaven Pharmaceutical Stock Soared Today
See More Headlines
Receive PBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter.

PBSV Company Calendar

Last Earnings
9/14/2022
Today
12/01/2022
Fiscal Year End
10/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Management consulting services
Sub-Industry
N/A
Sector
Business Services
Current Symbol
OTCMKTS:PBSV
CUSIP
N/A
CIK
1304161
Web
www.pharmabioserv.com
Phone
(787) 278-2709
Fax
787-796-5168
Employees
190
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
15.50
P/E Growth
N/A
Net Income
$-2,090,000.00
Net Margins
-19.85%
Pretax Margin
-18.86%
Return on Equity
-23.63%
Return on Assets
-18.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.08
Quick Ratio
9.08

Sales & Book Value

Annual Sales
$20.11 million
Price / Sales
0.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.81 per share
Price / Book
0.96

Miscellaneous

Outstanding Shares
23,460,000
Free Float
20,526,000
Market Cap
$18.18 million
Optionable
Not Optionable
Beta
0.34

Key Executives

  • Mr. Victor Sanchez (Age 51)
    CEO, Pres & Pres of European Operations
    Comp: $346.55k
  • Ms. Elizabeth Plaza (Age 58)
    Founder & Sr. Strategic Consultant
    Comp: $69.92k
  • Mr. Pedro J. Lasanta (Age 62)
    CFO, VP of Fin. & Admin. and Sec.
    Comp: $250.6k
  • Ms. Miriam Marrero M.B.A.
    HR Mang.

Key Competitors

View All Competitors













PBSV Stock - Frequently Asked Questions

How have PBSV shares performed in 2022?

Pharma-Bio Serv's stock was trading at $1.03 at the start of the year. Since then, PBSV stock has decreased by 24.8% and is now trading at $0.7750.
View the best growth stocks for 2022 here.

How were Pharma-Bio Serv's earnings last quarter?

Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) announced its quarterly earnings data on Wednesday, September, 14th. The company reported $0.01 EPS for the quarter. The company earned $4.77 million during the quarter. Pharma-Bio Serv had a negative net margin of 19.85% and a negative trailing twelve-month return on equity of 23.63%.

How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv?

Pharma-Bio Serv announced a dividend on Friday, February 18th. Shareholders of record on Friday, February 25th will be paid a dividend of $0.075 per share on Tuesday, March 15th. This represents a yield of 16.13%. The ex-dividend date of this dividend is Thursday, February 24th.
Read our dividend analysis for PBSV.

What other stocks do shareholders of Pharma-Bio Serv own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE).

What is Pharma-Bio Serv's stock symbol?

Pharma-Bio Serv trades on the OTCMKTS under the ticker symbol "PBSV."

How do I buy shares of Pharma-Bio Serv?

Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharma-Bio Serv's stock price today?

One share of PBSV stock can currently be purchased for approximately $0.77.

How much money does Pharma-Bio Serv make?

Pharma-Bio Serv (OTCMKTS:PBSV) has a market capitalization of $18.18 million and generates $20.11 million in revenue each year. The company earns $-2,090,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does Pharma-Bio Serv have?

The company employs 190 workers across the globe.

How can I contact Pharma-Bio Serv?

Pharma-Bio Serv's mailing address is Pharma-Bio Serv Building Suite 6 Road 696, DORADO PR, 00646. The official website for the company is www.pharmabioserv.com. The company can be reached via phone at (787) 278-2709, via email at scottg@corprominence.com, or via fax at 787-796-5168.

This page (OTCMKTS:PBSV) was last updated on 12/1/2022 by MarketBeat.com Staff